Is it essential for basic scientists and clinicians to work next door to each other to deliver the best results for human health? The short answer is yes, at least in the view of Britain's Medical Research Council (MRC), the government agency that funds much of biomedical research in the UK. This month, the MRC is seeking approval from the UK Treasury to move its largest establishment, the internationally respected National Institute for Medical Research (NIMR), from suburban Mill Hill in north London to the city center, at a cost of more than £320 million (US $605 million). After a debate over the institute's future that has lasted almost four years, a decision from the Treasury is expected very soon.
The NIMR has a proud history dating back to 1913. Discoveries by its researchers include the influenza virus, acetylcholine and the nature of neurotransmitters, interferon, the nature of immunological tolerance, and the sex-determining gene. Among its alumni, NIMR boasts five Nobel prize winners, including the immunologist Peter Medawar and A.J.P. Martin, who developed gas chromatography. The institute today, with a budget of £25 million (US $47 million) and more than 700 staff members, is recognized for its work on infection and immunity, developmental biology and genetics, neuroscience, and structural biology. Its future is of interest to scientists outside the UK as well as nationally not only because of its stature but because the changes it faces typify much broader shifts in the way biomedical research is being funded worldwide.
For some, the proposed move is an exciting step. "The renewed NIMR will potentially be the most powerful biomedical research environment in the UK," claims the MRC. If approved by the Treasury, the proposed new institute will not be wholly owned by the MRC but instead will be a partnership with University College London (UCL). It will be sited next door to UCL and minutes from University College Hospital. As well as giving its biomedical researchers access to other basic scientists at UCL, the council's key aim is to improve the two-way links between bench researchers and clinicians. Like other public funding bodies on both sides of the Atlantic, including the US National Institutes of Health (NIH), the MRC is keen to intensify its efforts in translational research.
But some NIMR researchers are concerned. They question the evidence that physical proximity is necessarily the best way for scientists to work together in the 21 st century. They point out that the potential benefits of the move are uncertain, whereas its costs are real, both to the public purse and, in the medium term, to the ongoing research activities of NIMR. "You have an institute at Mill Hill that functions well and is renowned," says Robin Lovell-Badge, head of developmental genetics at NIMR who, with Peter Goodfellow, discovered SRY, the sex-determining gene, in 1991. "I personally think it is fine for the MRC to build an institute to strengthen translational research in central London, but it would have been more imaginative to start a new one, instead of moving the NIMR." Having just been awarded an NIH grant for $3 million to study treatments for stroke, together with colleagues at London's King's College and two US institutes, Lovell-Badge points out that he is already doing translational research. "It just emphasises to me that we don't need to be located next to anyone to work with them," he says.
Some researchers fear that a move will also have a negative impact on the institute's basic science. "What frightens me," says Jonathan Stoye, head of NIMR's division of virology, "is that there is a calculation that says you can improve translational research by moving us, but there is no hard evidence that you will improve outputs that way…. What you need to do is facilitate links between researchers and clinicians, not put buildings next to each other."
Stoye points out that NIMR already works with a long list of other hospitals in different locations. For example, in a Lancet paper last month, NIMR scientists reported a new test for active tuberculosis infection that they had developed in collaboration with researchers at St. George's Hospital Medical School on the opposite side of London.
The tensions over the NIMR's future reflect a growing debate over how best to support high-quality biomedical science. In the public sector, in Europe and the US alike, funding bodies are under political pressure to show that taxpayers' money delivers results for people's health. In the US, the NIH Roadmap for medical research, launched in 2003, reaffirmed the need for intensified translational efforts as part of its move to "re-engineer" clinical research. In Britain, the MRC has been pushing for scientists to work more closely with clinicians for years, but in 2003 it formally made translational research a priority in its strategic plan for the decade. "The government, through the research councils, needs to be keeping its customers happy," says Richard Henderson, director of the
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MRC's Laboratory of Molecular Biology (LMB) in Cambridge.
Henderson has not failed to spot the contrast between the agenda of the publicly funded research agencies and those of some private foundations. The Howard Hughes Medical Institute has just invested half a billion dollars in a state-of-the-science campus, deliberately sited 30 miles from Washington DC in the Virginia countryside. Janelia Farm, due to open this month, has been designed to give high-calibre scientists the freedom to pursue long-range, highrisk research questions "without distraction." Ironically, Janelia Farm's head, Gerald Rubin, has said that he modeled elements of the new campus on the original LMB, where he did his PhD. Henderson argues that, because private foundations such as the Howard Hughes have fewer stakeholders to answer to than the publicsector funding bodies, they are free to fund visibly separate research initiatives that clearly demonstrate their investment rather than allowing their funds to get blurred with those from other sources. As another example of this separation, Henderson cites the Wellcome Trust's Sanger Institute outside Cambridge, with almost 2000 researchers and with 90% funding by the Trust.
The current status of the NIMR belies a long and fraught debate over its future. In 2003, the MRC reviewed its plans for capital investment over the next decade not only for NIMR but also for other major MRC institutes. The review gave the NIMR full marks for its research but concluded that its facilities would need to be modernized to keep competitive, and the case for keeping it on its present Mill Hill site was "not strong," given the council's broader push for bringing stand-alone institutes closer to other research bases. The MRC then set up a task force to re-examine the options, although modernizing the existing Mill Hill institute was the one option not under consideration. Privately, some scientists suspected that the MRC had a hidden agenda to close Mill Hill, or that its plans were the result of empire-building by clinicians keen to regain some of the status that clinical research has lost in recent decades. That suspicion is vigorously dismissed by Colin Blakemore, the MRC's Chief Executive. "If there is a hidden agenda then after three years at the MRC I am still unaware of where it is hidden," he told Cell. "The only agenda is to achieve the best possible future for the institute and its research in a promising new era."
Late in 2004, the MRC accepted the recommendations of the task force that the institute should move alongside a university and teaching hospital, with a renewed focus on "basic and translational research," while remaining in London. This recommendation was made on the condition that the new institute would ultimately be an improvement on the existing one. In 2005 the MRC agreed to a partnership with University College London. Staff from the MRC, the NIMR, and UCL drew up a draft business plan for the new institute. The MRC estimated then that the new institute would cost about £320 million. This would be funded partly by £100 million from the MRC, with a further £140 million from a separate government pot administered by the Office of Science and Innovation (OSI), called the Large Facilities Capital Fund. The balance would come mainly from UCL and the proceeds of selling the Mill Hill site. Earlier this year, the MRC bought the site adjacent to UCL but could not press ahead with its plans without approval from OSI and the Treasury. As Cell went to press, the final version of the business plan was to be presented to the MRC Council and then, following the Council's approval, will be sent straight to the Treasury. The MRC expects a response from the Treasury before the end of the year.
Assuming the plan goes ahead, it will be at least 6 years before the new institute is ready. The design phase will take until 2009 and building is due to be completed by 2012. Because the future of NIMR has taken longer to decide than originally expected, the timing of the building phase may pose a headache for the MRC. Sceptics point out that by the time the MRC calls the builders in, every builder in London will already be committed to construction of the infrastructure for the 2012 Olympics, so costs are likely to spiral upwards. Blakemore confirms that the estimated cost of the proposed institute has risen, but for "explicable" reasons.
NIMR researchers accept that the proposed central London institute could be adequate. However, they are worried about other options that the Treasury has required the MRC to explore in its business plan as a means to justify its preferred option for a new institute in central London. These include moving the institute out of south-east England, or leaving the NIMR without new investment in its current aging buildings-the "donothing" option. Blakemore says that these are not serious options but simply exercises to explain MRC's reasons for its preferred plan. Without investment, the current NIMR site has at most a life expectancy of 20 years and the MRC Council has already concluded that the site has no long-term future, he says. "We know that the do-nothing option is literally not an option, and the Treasury is unlikely to challenge that," says Blakemore. Likewise, he accepts that locating the institute outside southeast England would effectively break up its existing teams. "One of our aims is to keep the excellent scientists at NIMR working together."
Even if the Treasury approves the preferred option, there are many important details that have yet to be resolved. "It is clearly very good that the MRC is thinking of investing £320 million in the institute and its continued success," says LovellBadge. "But we are very worried about the practicalities of the move, and whether the site is sufficient." One obvious issue is size. The NIMR currently has a campus of more than 40 acres and includes sophisticated animal research and containment laboratories. The new site covers less than one acre. Although the MRC has argued that it could fit most of the institute's existing laboratory space into a high-rise building on this site, it has not ruled out the possibility that some scientists could be based elsewhere.
A second issue is the animal facilities. Some scientists understand that the animals could end up being sited 2 miles from the new building, while others fear that moving the animal facilities could lose vital research time. It could take 2 years or more after a move to re-establish specific lines of animals, forcing scientists either to wait or establish parallel animal facilities during the transition. There are also questions about whether the institute's containment facilities for infectious agents can be moved to central London. "We welcome the investment in a new institute, but it is a major concern for me if we do not have those facilities on site," says Stoye.
Yet more uncertainty surrounds the leadership of the institute. John Skehel, the director since 1987, retired last month. Although the MRC has tried to recruit a new director, it is unlikely to get one until the detailed future of the new institute is agreed. Although the MRC will not confirm any names, many scientists know that its preferred candidate is Scott Fraser, professor of bioengineering at Caltech in Pasadena, California. "I have always thought that NIMR is one of the real crown jewels," says Fraser, whose bioimaging skills and previous collaboration with NIMR teams have put him in the spotlight. He confirmed before Cell went to press that he was in "advanced discussions" with the MRC but stresses that there are still many undecided issues, as well as other opportunities for him to consider. Meanwhile, the MRC has asked 68-year-old Keith Peters, former head of the medical school at Cambridge University, to step in as interim caretaker. Until a permanent director is appointed, recruitment has been frozen and insiders report that some teams are now in need of new members, although, surprisingly, given the continued uncertainty, no senior scientists have yet left NIMR.
Many outside the NIMR hope that the years of argument over its future can be laid to rest. Richard Henderson, head of the MRC's Laboratory of Molecular Biology, takes a philosophical view. He acknowledges the fears of NIMR researchers but also understands the need for a government-funded enterprise to be accountable to its stakeholders and to serve its communities to the best standard possible. For that reason, he thinks it is "reasonable" that the MRC wants a new institute alongside a university and hospital. "The only question is this," he says: "If you have got something that works, why change it?" The MRC could have developed its new institute with UCL while also maintaining the current site and NIMR infrastructure, he believes.
Clearly, the question of whether clinicians and basic scientists should rub shoulders daily is still unanswered. Advocates of the approach admit that there is no hard evidence to support the idea that sharing space results in better work, and they doubt it will ever be possible to document this in a systematic way. But they say they are persuaded of its benefits by their own working experience. "I do think in general there is an advantage in proximity," says Henderson. A similar view is held by Mark Walport, director of the Wellcome Trust, and formerly chair of the division of medicine at Imperial College London's Hammersmith campus. "I think there are real advantages," he says. He points to the successful links between groups of institutions elsewhere. One example, he suggests, is Massachusetts General Hospital, MIT, and Harvard (although this network has evolved rather than being deliberately created). And, Walport argues, since the MRC moved its Clinical Sciences Centre to the Hammersmith Hospital, it has been working "incredibly well." Of the proposed NIMR move he says: "Asked if this is a piece of cosmic irrationality-no, I don't think so. We need as strong a biomedical science endeavour as possible, and we can never afford to stand still."
